Login to Your Account

Other News To Note

Thursday, August 2, 2012
• Depomed Inc., of Menlo Park, Calif., submitted a new drug application for Serada to the FDA. The extended-release formulation of gabapentin is in development to treat menopausal hot flashes. The company conducted three Phase III studies (BREEZE 1, 2 and 3), reporting in October 2011 that Serada achieved its primary BREEZE 3 endpoints at four weeks but faltered at 12 weeks, hitting the severity endpoint but failing to reduce frequency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription